[
  {
    "ts": null,
    "headline": "Top Biotech Stocks Riding The Rally",
    "summary": "Biotech stocks have rebounded in 2025, boosted by strong product launches, trial results, FDA approvals, and M&A. Discover top biotech stocks fueling the rally.",
    "url": "https://finnhub.io/api/news?id=023352e0cc67e9e5869fe3227e780ce0ce1155458ff7a2d3435ecbcad72043f4",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762269335,
      "headline": "Top Biotech Stocks Riding The Rally",
      "id": 137321725,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155151969/image_155151969.jpg?io=getty-c-w1536",
      "related": "INCY",
      "source": "SeekingAlpha",
      "summary": "Biotech stocks have rebounded in 2025, boosted by strong product launches, trial results, FDA approvals, and M&A. Discover top biotech stocks fueling the rally.",
      "url": "https://finnhub.io/api/news?id=023352e0cc67e9e5869fe3227e780ce0ce1155458ff7a2d3435ecbcad72043f4"
    }
  },
  {
    "ts": null,
    "headline": "Prelude Therapeutics Announces Strategic Business Update",
    "summary": "Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially int",
    "url": "https://finnhub.io/api/news?id=7c5b0130af57e7cc4f280437b8de0148439e88ae20b8928828f33d232d5dc60d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762257900,
      "headline": "Prelude Therapeutics Announces Strategic Business Update",
      "id": 137313170,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Prelude to prioritize development of mutant selective JAK2V617F JH2 inhibitor and KAT6A selective degrader programs Pausing further clinical development of SMARCA2 selective degrader programs JAK2V617F option agreement with Incyte, as previously announced, includes upfront payment of $35 million, a $25 million equity investment and $100 million if option is exercised Cumulative capital expected to fund planned operations into 2027 based on the Company’s preliminary estimates, and potentially int",
      "url": "https://finnhub.io/api/news?id=7c5b0130af57e7cc4f280437b8de0148439e88ae20b8928828f33d232d5dc60d"
    }
  },
  {
    "ts": null,
    "headline": "Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors",
    "summary": "Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa",
    "url": "https://finnhub.io/api/news?id=013f2b963a7e66bde21b6b233077f7dfb4c0cf5a3f17c66f51432e9d5ec80ea5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762257660,
      "headline": "Prelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors",
      "id": 137313172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte secures an exclusive option to acquire Prelude’s mutant selective JAK2V617F JH2 inhibitor program Mutant selective JAK2V617F JH2 inhibitors have disease-modifying potential in treating patients living with myeloproliferative neoplasms (MPNs) Prelude to receive a $35 million upfront payment and $25 million strategic equity investment, $100 million if Incyte were to exercise the option to acquire the program, and up to $775 million in additional potential milestones plus royalties on net sa",
      "url": "https://finnhub.io/api/news?id=013f2b963a7e66bde21b6b233077f7dfb4c0cf5a3f17c66f51432e9d5ec80ea5"
    }
  },
  {
    "ts": null,
    "headline": "Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage",
    "summary": "We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning streak to a third straight day to hit a new all-time high as investors took heart from an investment firm’s bullish coverage for […]",
    "url": "https://finnhub.io/api/news?id=a0717317d72c0bc206701036ad0432a09a477d0266099629a9743e69a496f058",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762255110,
      "headline": "Incyte (INCY) Extends Climb, Hits New High on Bullish Coverage",
      "id": 137313174,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning streak to a third straight day to hit a new all-time high as investors took heart from an investment firm’s bullish coverage for […]",
      "url": "https://finnhub.io/api/news?id=a0717317d72c0bc206701036ad0432a09a477d0266099629a9743e69a496f058"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Drop as Fed Caution Weighs",
    "summary": "The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...",
    "url": "https://finnhub.io/api/news?id=4aa73b85898c9ebed210ed5ee658c5a25ca0f02152c761868b1aa54254eae944",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762251482,
      "headline": "S&P 500 Futures Drop as Fed Caution Weighs",
      "id": 137312760,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The Morning Bull - US Market Morning Update Tuesday, Nov, 4 2025 US stock futures are sliding premarket as investors digest hawkish signals from the Federal Reserve and ongoing signs of strain in the manufacturing sector. With Fed officials making it clear that a December rate cut is not guaranteed, and manufacturing data painting a mixed, uncertain picture, market sentiment is becoming more cautious as investors weigh the impact of elevated yields and weaker production on broader economic...",
      "url": "https://finnhub.io/api/news?id=4aa73b85898c9ebed210ed5ee658c5a25ca0f02152c761868b1aa54254eae944"
    }
  },
  {
    "ts": null,
    "headline": "The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call",
    "summary": "Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside the launch traction of Niktimvo, as major contributors to the quarter’s strong operational performance. CEO William Meury emphasized the company’s ongoing cost discipline and strategic investment in core R&D programs. He noted, “Our job right now is to keep [the fundamentals] that way and to identif",
    "url": "https://finnhub.io/api/news?id=2e079608f9350b2df98e4e95980561b8b179d012c8f9a6b7ff4cbcb3885a0a46",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762234721,
      "headline": "The 5 Most Interesting Analyst Questions From Incyte’s Q3 Earnings Call",
      "id": 137313177,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte’s third quarter saw revenue and profit surpass Wall Street’s expectations, yet the market responded negatively. Management identified robust demand for key drugs Jakafi and Opzelura, alongside the launch traction of Niktimvo, as major contributors to the quarter’s strong operational performance. CEO William Meury emphasized the company’s ongoing cost discipline and strategic investment in core R&D programs. He noted, “Our job right now is to keep [the fundamentals] that way and to identif",
      "url": "https://finnhub.io/api/news?id=2e079608f9350b2df98e4e95980561b8b179d012c8f9a6b7ff4cbcb3885a0a46"
    }
  }
]